Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Dose Finding Study of Oral MP470, a Multi-targeted Tyrosine Kinase Inhibitor, in Combination With Standard-of-Care Chemotherapy Regimens

NCT00881166 is registered in ClinicalTrials.gov with Astex Pharmaceuticals, Inc. as lead sponsor.

NCT NCT00881166
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00881166 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Dose Finding Study of Oral MP470, a Multi-targeted Tyrosine Kinase Inhibitor, in Combination With Standard-of-Care Chemotherapy Regimens
Lead sponsor
Astex Pharmaceuticals, Inc.
Phase
Phase 1
Overall status
Completed
Start date
November 30, 2007
Completion date
December 31, 2009
Enrollment
101 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

malignant disease